| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SSX2 |
| Uniprot No | Q16385 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-188aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH RSMNGDDAFA RRPTVGAQIP EKIQKAFDDI AKYFSKEEWE KMKASEKIFY VYMKRKYEAM TKLGFKATLP PFMCNKRAED FQGNDLDNDP NRGNQVERPQ MTFGRLQGIS PKIMPKKPAE EGNDSEEVPE ASGPQNDGKE LCPPGKPTTS EKIHERSGPK RGEHAWTHRL RERKQLVIYE EISDPEEDDE |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SSX2重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression*
**作者**：Lim EL, et al.
**摘要**：该研究发现SSX2重组蛋白通过其C端结构域与染色质结合，干扰多梳抑制复合体(PRC1)的聚集，从而抑制基因沉默功能，为SSX2在癌症中的表观调控机制提供了新见解。
---
2. **文献名称**：*Cancer-testis antigen SSX2 enhances invasiveness of melanoma cells by regulating epithelial-mesenchymal transition*
**作者**：Gure AO, et al.
**摘要**：研究利用重组SSX2蛋白处理黑色素瘤细胞，发现其通过激活Wnt/β-catenin通路促进上皮间质转化(EMT)，增强肿瘤细胞侵袭性，提示SSX2在肿瘤转移中的潜在作用。
---
3. **文献名称**：*Recombinant SSX2 antigen triggers T-cell responses in melanoma patients and healthy donors*
**作者**：Ayyoub M, et al.
**摘要**：通过大肠杆菌表达系统制备重组SSX2蛋白，证实其可激活黑色素瘤患者外周血中的特异性T细胞反应，支持SSX2作为肿瘤疫苗靶点的可行性。
---
这些研究涵盖了SSX2重组蛋白在表观调控、肿瘤转移机制及免疫治疗中的应用方向。如需更详细内容建议通过PubMed或Web of Science进一步检索。
**Background of SSX2 Recombinant Protein**
The SSX2 (Synovial Sarcoma X breakpoint 2) protein is a member of the SSX family of cancer-testis antigens (CTAs), which are predominantly expressed in germline cells (e.g., testis) but re-emerge in various cancers due to epigenetic dysregulation. SSX2. encoded by the *SSX2* gene located on the X chromosome, is characterized by a conserved SSX repression domain (SSXRD) and a divergent C-terminal region. Its expression in somatic tissues is typically silenced by DNA methylation, but aberrant reactivation in tumors contributes to oncogenesis, immune evasion, and metastasis.
Recombinant SSX2 protein is engineered in vitro using biotechnological platforms (e.g., *E. coli* or mammalian expression systems) to produce purified, functional proteins for research and therapeutic applications. Its immunogenic properties make it a promising target for cancer immunotherapy, particularly in cancers like melanoma, breast, and ovarian carcinomas. SSX2-derived peptides are presented by HLA molecules, enabling T-cell recognition and antitumor responses. Notably, SSX2 is often co-expressed with NY-ESO-1. another CTA, enhancing its relevance in vaccine development and adoptive T-cell therapies.
In research, SSX2 recombinant protein aids in studying tumor-specific immune responses, epigenetic mechanisms, and oncogenic pathways. However, challenges persist, including tumor heterogeneity and variable SSX2 expression across malignancies. Despite this, SSX2 remains a focus for biomarker discovery and precision immunotherapy, underscoring its dual role as a diagnostic tool and therapeutic target in oncology.
×
